摘要
目的探讨了扩张型心肌病患者给予沙库巴曲缬沙坦钠治疗的效果。方法选取了2018年2月—2020年2月我院收治的120例扩张型心肌病患者,作为本次的研究对象。随机将120名患者划分为观察组(n=60)和对照组(n=60)。两组在接受治疗的过程中,对对照组给予缬沙坦胶囊治疗,对观察组给予沙库巴曲缬沙坦钠进行治疗。对两组治疗前后的心功能相关指标、治疗后不良反应发生情况、临床治疗效果以及两组患者治疗前后血浆NT-pro与BNP水平,进行了对比,分析了扩张型心肌病患者在给予沙库巴曲缬沙坦钠的行临床治疗效果。结果2组患者经过阶段性治疗后,治疗前2组心功能指标,差异无统计学意义(P>0.05)。治疗后心功能对比治疗前具有提升,观察组LVEF、LVEDD功能明显优于对照组,差异有统计学意义(P<0.05);对2组不良反应发生情况进行对比,两组患者低血压、血管性水肿、高钾血症和肾功能损伤等不良反应发生率,差异无统计学意义(P>0.05);对2组临床治疗效果进行比较,观察组的临床疗效高与对照组,差异有统计学意义(P<0.05);对2组治疗前后血浆NT-pro与BNP水平进行比较,治疗前2组血浆NT-pro与BNP水平,差异无统计学意义(P>0.05)。治疗后,2组血浆NT-pro与BNP水平低于治疗前,差异有统计学意义(P<0.05)。治疗后,观察组血浆NT-pro与BNP水平低于对照组,差异有统计学意义(P<0.05);结论对扩张型心肌病患者给予沙库巴曲缬沙坦钠进行治疗过程中,具有较好的应用临床效果,可以有效改善患者的慢性心衰病情,降低治疗过程中的不良反应发生率,提升治疗效果和安全性。
Objective To explore the effect of valsartan sodium sacubatrile in patients with dilated cardiomyopathy.Methods Forty patients with dilated cardiomyopathy admitted to our hospital from February 2018 to February 2020 were selected as the subjects of this study.One hundred and twenty patients were randomly divided into observation group(n=60)and control group(n=60).During the course of treatment,the two groups were given valsartan capsules to the control group,and the observation group was given valsartan sodium.The indexes of cardiac function before and after treatment,the incidence of adverse reactions after treatment,the clinical treatment effect,and the plasma NT-pro and BNP levels of the two groups of patients before and after treatment were compared.The clinical effect of sakobactrum valsartan sodium on dilated cardiomyopathy was analyzed.Results After the patients in the two groups had undergone staged treatment,there was no significant difference in cardiac function indexes between the two groups before treatment(P>0.05).After treatment,the cardiac function is improved compared with that before treatment.The LVEF and LVEDD functions of the observation group are significantly better than the control group(P<0.05);the adverse reactions of the two groups are compared.The two groups of patients have low blood pressure,angioedema,and hyperkalemia there was no significant difference in the occurrence of adverse reactions between syndrome and renal function damage(P>0.05);comparing the clinical treatment effects of the two groups,the clinical efficacy of the observation group was higher than that of the control group(P<0.05);plasma NT-pro before and after treatment in the two groups compared with BNP levels,there was no significant difference in plasma NT-pro and BNP levels between the two groups before treatment(P>0.05).After treatment,the plasma NT-pro and BNP levels of the two groups were lower than before treatment(P<0.05).After treatment,the plasma NT-pro and BNP levels in the observation group were lower than those in the control group(P<0.05).Conclusion The treatment of dilated cardiomyopathy patients with sacubatril valsartan sodium has a good clinical application the effect can effectively improve the patient's chronic heart failure,reduce the incidence of adverse reactions in the course of treatment,improve the treatment effect and safety.
作者
龚真
杨晶晶
GONG Zhen;YANG Jingjing(Department of Cardiology,Dangyang People's Hospital,Dangyang Hubei 444100,China)
出处
《中国继续医学教育》
2021年第27期142-146,共5页
China Continuing Medical Education
关键词
沙库巴曲缬沙坦钠
扩张型心肌病
心脏功能
不良反应
临床疗效
应用效果
sacubatril valsartan sodium
dilated cardiomyopathy
cardiac function
adverse reactions
clinical efficacy
application effect
